Skip to main content

Table 2 Summary of decision-tree inputs

From: Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

  Input Reference
ALK determination strategies
 IHC 37.2% [18]
 FISH 11.6% [18]
 Reflex 46.5% [18]
 NGS 4.7% [18]
Positivity rate in selected biomarkers
 ALK+ 3.4% [18]
 EGFR+ 13.6% [18]
 ROS1+ 2% [18]
 PD-L1 ≥ 50% 33% [18]
 Percentage of invalid results
 With IHC or FISH 2.6% [18]
 With NGS 3.4% [19]
Rebiopsy
 Probability of rebiopsy if invalid 77.1% [20]
Specificity and sensitivity
 IHC 97.9% / 96.8% [21]
 FISH 99.8% / 90.9% [22]
 NGS 100% Assumptiona
  1. ALK anaplastic lymphoma kinase, IHC immunohistochemistry, FISH fluorescent in situ hybridization, NGS next-generation sequencing, EGFR epidermal growth factor receptor
  2. aConsidered the gold standard in the determination of ALK